Novo Nordisk announced on 11/8/2023 that their long-acting insulin, Levemir®, will be phased out from United States markers completely discontinuing by December 2024. It cited manufacturing constraints,…
Read More
FDA recall warning: April 6, 2023 Abbott pharmaceuticals has issued a warning impacting four million readers for glucose monitors after reports that devices were overheating and…
Read More
IBSA Pharma Inc. has announced a voluntary recall of 27 lots of TIROSINT®-SOL (levothyroxine sodium) Oral Solution due to concern for subpotency. Company testing revealed a…
Read More
FDA notice on sitagliptin contamination The Food and Drug Administration (FDA) recently reported the detection of a nitrosamine impurity (Nitroso-STG-19, known as NTTP) in samples of…
Read More
Not a member yet? Join the largest Pediatric Endocrine community and unlock a host of tools, resources, and enhance your network! Click here to learn more.